SEPTInvestingStart Free
Stocks/VTRS/SEC Filings/8-K Nov 5, 2026

VTRS 8-K: Guidance raise

Viatris

Filed with the SEC on Nov 5, 2026 · accession 0001792044-26-000053

VTRS filed a 8-K (current report) with the SEC on Nov 5, 2026. Viatris reported Q3 2026 total revenues of $3.75 billion, a GAAP net loss of $325 million, and adjusted EBITDA of $1.20 billion, while raising the midpoints of its full-year 2026 financial guidance across all key metrics. The stock moved -1.3% by the first close after the filing.

Summary of the filing

Viatris reported Q3 2026 total revenues of $3.75 billion, a GAAP net loss of $325 million, and adjusted EBITDA of $1.20 billion, while raising the midpoints of its full-year 2026 financial guidance across all key metrics. The company also highlighted regulatory approvals for RYZUMVI in the U.S. and WAKIX in Japan, and its planned acquisition of Pacira BioSciences expected to close by end of November.

For details, click here →How to read a 8-K →

Key details

Total revenues for Q3 2026$3.7B
U.S. GAAP net loss for Q3 2026-$325.3M
Adjusted EBITDA for Q3 2026$1.2B
Adjusted EPS for Q3 2026$1
Capital returned to shareholders year to date$717.0M
IssuerViatris Inc.
Planned acquisition targetPacira BioSciences
CeoScott A. Smith
Interim cfo, chief accounting officer & corporate controllerPaul Campbell

How VTRS stock reacted

Close before

$19.22

Nov 4, 2026

First close after

-1.30%

$18.97

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for VTRS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for VTRS?

Click here

Frequently asked questions

What did VTRS file with the SEC on Nov 5, 2026?

VTRS filed a 8-K (Guidance raise). Viatris reported Q3 2026 total revenues of $3.75 billion, a GAAP net loss of $325 million, and adjusted EBITDA of $1.20 billion, while raising the midpoints of its full-year 2026 financial guidance across all key metrics. The company also highlighted regulatory approvals for RYZUMVI in the U.S. and WAKIX in Japan, and its planned acquisition of Pacira BioSciences expected to close by end of November.

What does a guidance raise mean for VTRS stock?

Guidance is the company’s own forecast. Investors price stocks on the future, so a raise or cut often moves the stock more than the past quarter’s numbers.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did VTRS stock react to this filing?

VTRS closed at $19.22 before the filing and $18.97 on Nov 5, 2026 (-1.30%).

Other VTRS SEC filings

  • 10-Q · SEC filingNov 5, 2026
  • 8-K · AcquisitionOct 8, 2026
  • 8-K · Guidance raiseAug 6, 2026
  • 10-Q · Cfo changeAug 6, 2026
  • 8-K · Material agreementJul 1, 2026
  • 8-K · Material agreementJun 18, 2026
  • 8-K · Material agreementJun 15, 2026
  • 8-K · SEC filingMay 15, 2026
  • 8-K · SEC filingMay 7, 2026
  • 10-Q · Executive departureMay 7, 2026

Get alerts when VTRS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
VTRS overviewVTRS analysisVTRS newsLatest SEC filings
Source: SEC EDGAR filing 0001792044-26-000053. The summary and key details are extracted by SEPT from the filing and may contain errors. Price reaction uses daily closing prices. Not financial advice.